Free Newsletter
Stem cells take center stage in San Diego summit
The Stem Cell Summit wrapped up two days of discussions in San Diego with a focus on some of the therapies that are either already in use or close to it. There's already a small market to use stem cells to make synthetic discs for the spine, but a lineup of companies in the adult stem cell field--led by stem cells drawn from bone marrow, blood and fat--are pushing experimental therapies that are already at mid- to late-stage development, according to Robin Young, who helped organize The Stem Cell Summit. About 300 executives took part in the summit. Burrill & Co. hosted a gathering on stem cell advances this week as well, underscoring just how much fresh attention is being given to the emerging field.
- read the San Diego Union-Tribune report
ALSO: An appeals court in California heard arguments over the case against the state's $3 billion stem cell program. Observers felt the court seemed to favor the bond program against the arguments raised against it, but look for another appeal regardless of the outcome. The state stem cell institute, meanwhile, plans to issue $24 million in research grants tomorrow. Report
Related Articles:
Scientists tout adult stem cell study results. Report
Mature stem cells prove effective in cloning. Report
Increased versatility found in adult stem cell. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: